BioSpectrum announces the hits and misses of 2013
BioSpectrum Asia tracks the hits and misses of 2013 from the Asian life sciences industry
What were the biggest hits and misses of 2013?
Asia attracted a lot of interest from foreign multinational giants in the year 2013. This not only led to the increase in the number of acquisitions and mergers (M&A), it also led to a rise in investments and joint ventures. BioSpectrum has launched its special feature with a round up of all that happened in the last 12 months and presents Flashback 2013.
This elaborate feature has all the hits and misses of the year from the Asian life sciences industry, the path breaking products and ground breaking medical devices that made it to the top five in Asia through the year. Furthermore, the special report features a roundup of 2013’s highlights from India, Malaysia, Taiwan, Thailand, Australia, Korea, Singapore, Malaysia and other prominent countries from the APAC region.
All the burning issues, starting from the biggest settlement ever made to the US drug regulator, the Food and Drug Administration (FDA), over quality issues of drugs; the darkest revelation of the year in the drug business – GlaxoSmithKline’s corrupt actions in China; and the landmark verdict of the year that had the US Supreme Court declare that ‘Human Genes cannot be Patented’ have been covered elaborately in this feature.
BioSpectrum brings to its readers, 2013’s bests and hall of shame in its special issue. Click on the link to read on here.
